Treatment of even mild to moderate Crohn's disease is a long-term challenge due to its remitting and relapsing course

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.25, Iss.6, 2009-06, pp. : 10-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Cost Effectiveness of Interferon- -1a in the Treatment of Relapsing-Remitting Multiple Sclerosis: An Econometric Model

By Lepen C.

Clinical Drug Investigation, Vol. 23, Iss. 9, 2003-01 ,pp. : 571-581

Adis International

Access to resources Recommend Favorite

Mild to Moderate Crohn's Disease: An Evidence-Based Treatment Algorithm

By Wong Karen Bressler Brian

Drugs, Vol. 68, Iss. 17, 2008-01 ,pp. : 2419-2425

Adis International

Access to resources Recommend Favorite

An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients

Current Pharmaceutical Design, Vol. 18, Iss. 29, 2012-10 ,pp. : 4475-4484

Bentham Science Publishers

Access to resources Recommend Favorite

Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-&bgr;-1b treatment in relapsing remitting MS

By Goertsches Robert H Hecker Michael Koczan Dirk Serrano-Fernandez Pablo Moeller Steffen Thiesen Hans-Juergen Zettl Uwe K

Pharmacogenomics, Vol. 11, Iss. 2, 2010-02 ,pp. : 147-161

Future Medicine

Access to resources Recommend Favorite

Interferons in Relapsing-Remitting Multiple Sclerosis: Are There Benefits from Long-Term Use?

By Oscar Fernández

CNS Drugs, Vol. 18, Iss. 15, 2004-01 ,pp. : 1057-1070

Adis International

Access to resources Recommend Favorite